{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T19:26:59Z","timestamp":1768073219223,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy of sequential treatment with ipilimumab and nivolumab following progression on nivolumab monotherapy in individuals with advanced, non\u2010clear\u2010cell renal cell carcinoma (nccRCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      UNISoN (ANZUP1602;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03177239\">NCT03177239<\/jats:ext-link>\n                      ) was an open\u2010label, single\u2010arm, phase 2 clinical trial that recruited adults with immunotherapy\u2010na\u00efve, advanced nccRCC. Participants received nivolumab 240\u2009mg i.v. two\u2010weekly for up to 12\u2009months (Part 1), followed by sequential addition of ipilimumab 1\u2009mg\/kg three\u2010weekly for four doses to nivolumab if disease progression occurred during treatment (Part 2). The primary endpoint was objective tumour response rate (OTRR) and secondary endpoints included duration of response (DOR), progression\u2010free (PFS) and overall survival (OS), and toxicity (treatment\u2010related adverse events).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 83 participants were eligible for Part 1, including people with papillary (37\/83, 45%), chromophobe (15\/83, 18%) and other nccRCC subtypes (31\/83, 37%); 41 participants enrolled in Part 2. The median (range) follow\u2010up was 22\u2009(16\u201330) months. In Part 1, the OTRR was 16.9% (95% confidence interval [CI] 9.5\u201326.7), the median DOR was 20.7\u2009months (95% CI 3.7\u2010not reached) and the median PFS was 4.0\u2009months (95% CI 3.6\u20137.4). Treatment\u2010related adverse events were reported in 71% of participants; 19% were grade 3 or 4. For participants who enrolled in Part 2, the OTRR was 10%; the median DOR was 13.5\u2009months (95% CI 4.8\u201319.7) and the median PFS 2.6\u2009months (95% CI 2.2\u20133.8). Treatment\u2010related adverse events occurred in 80% of these participants; 49% had grade 3, 4 or 5. The median OS was 24\u2009months (95% CI 16\u201328) from time of enrolment in Part 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nivolumab monotherapy had a modest effect overall, with a few participants experiencing a long DOR. Sequential combination immunotherapy by addition of ipilimumab in the context of disease progression to nivolumab in nccRCC is not supported by this study, with only a minority of participants benefiting from this strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16190","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T18:50:50Z","timestamp":1700592650000},"page":"57-67","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non\u2010clear\u2010cell renal cell carcinoma"],"prefix":"10.1111","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-4130","authenticated-orcid":false,"given":"Ciara","family":"Conduit","sequence":"first","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Eastern Health Clinical School Monash University  Box Hill VIC Australia"},{"name":"Eastern Health  Melbourne VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.","family":"Goh","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Royal Brisbane and Women's Hospital  Herston QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Flinders Centre for Innovation in Cancer, Flinders Medical Centre  Bedford Park SA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Macquarie University  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole A.","family":"Harris","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"St George Hospital Cancer Care Centre  Kogarah NSW Australia"},{"name":"University of NSW South Wales  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pook","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Monash Health  Melbourne VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Krieger","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"GenesisCare North Shore  St Leonards NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Parnis","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Adelaide Cancer Centre  Kurralta Park SA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Underhill","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre  East Albury NSW Australia"},{"name":"Rural Medical School, Albury Campus University of New South Wales  Albury\u2010Wodonga NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Adams","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Macarthur Cancer Therapy Centre  Campbelltown NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Roncolato","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Macarthur Cancer Therapy Centre  Campbelltown NSW Australia"},{"name":"NHMRC Clinical Trials Centre University of Sydney  Camperdown NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Joshua","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"St Vincent's Hospital Sydney  Darlinghurst NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Fiona Stanley Hospital  Perth WA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth","family":"Prithviraj","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Ballarat Oncology and Haematology Services  Ballarat VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Morris","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Sunshine Coast University Hospital  Birtinya QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Harrison","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Royal Prince Alfred Hospital  Hunters Hill NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Begbie","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"North Coast Cancer Institute, Port Macquarie Base Hospital  Port Macquarie NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hovey","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Nelune Comprehensive Cancer Centre, Prince of Wales Hospital  Randwick, Sydney NSW Australia"},{"name":"Faculty of Medicine University of New South Wales  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"George","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Northwest Cancer Centre Tamworth Hospital  Tamworth NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Liow","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Monash Health  Melbourne VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma K.","family":"Link","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Centre for Biostatistics and Clinical Trials (BaCT), Peter MacCallum Cancer Centre The University of Melbourne  Melbourne VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"McJannett","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Gedye","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)  Sydney NSW Australia"},{"name":"Calvary Mater Newcastle  Waratah NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the UNISoN Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34180"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28151"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.02.013"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0319-9"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0475"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01692-z"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.05.010"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3233\/KCA-210012"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1214575"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2020.05.006"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.309"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02365"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA4503"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01944"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00276-0"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16092"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02295"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02938"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.107"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4576"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00515-X"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.014"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30907-0"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2218"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00152-5"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.03.015"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.014"},{"key":"e_1_2_8_35_1","unstructured":"National Comprehensive Cancer Network.Kidney Cancer Version 1.2024[cited 2023 Sep 14]. Available at:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4537"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06480-5"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.06.040"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:20:57Z","timestamp":1761740457000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":37,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/bju.16190"],"URL":"https:\/\/doi.org\/10.1111\/bju.16190","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"2023-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}